Daiichi Sankyo's blood clot and stroke prevention drug, edoxaban, has met its primary efficacy endpoint in a phase three clinical trial. The clinical trial, ENGAGE, was evaluating the ...
Phase 3 clinical trial results of Bristol-Myers Squibb and Pfizer's blood thinner, Eliquis, have been announced. The results showed that Eliquis (apixaban) is as effective as the current standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback